Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-PROT-142

ABSTRACT: Proteomic characterization of human hepatocellular carcinoma (HCC) tumor biopsies

PROVIDER: E-PROT-142 | ExpressionAtlas | 2024-06-05

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-PROT-142-MappedToGeneID.txt	Txt
	E-PROT-142-analysis-methods.tsv	Tabular
	E-PROT-142-configuration.xml	Xml
	E-PROT-142-factors.xml	Xml
	E-PROT-142-pipeline.pdf	Pdf

Items per page:

1 - 5 of 11

Similar Datasets

E-GEOD-33006

Project description:Gene expression profiles from the hepatocellular carcinoma (HCC) tissues

2025-01-24 | E-GEOD-33006 | ExpressionAtlas

E-GEOD-55048

Project description:Transcriptomic characterization of Hepatocellular Carcinoma with CTNNB1 mutation

2025-01-24 | E-GEOD-55048 | ExpressionAtlas

E-GEOD-33294

Project description:Transcriptome sequencing of human hepatocellular carcinoma

2025-01-24 | E-GEOD-33294 | ExpressionAtlas

Proteomic characterization of human hepatocellular carcinoma (HCC) tumor biopsies

Project description:We analyzed the proteome of tumor and matched non-tumor biopsies from 51 treatment-naive Hepatocellular carcinoma (HCC) patients by DIA (SWATH). Thereby we aim to find subgroups of patients characterized by specific pathway activation. Furthermore, we aim to find novel factors involved in HCC development and novel biomarkers.

2022-03-14 | PXD025705 | Pride

Phospho-proteomic characterization of human hepatocellular carcinoma (HCC) tumor biopsies

Project description:We analyzed the phospho-proteome of tumor and matched non-tumor biopsies from 51 treatment-naive Hepatocellular carcinoma (HCC) patients by label-free DDA. Thereby we aim to find subgroups of patients characterized by specific pathway activation. Furthermore, we aim to find novel factors involved in HCC development and novel biomarkers.

2022-03-14 | PXD025836 | Pride

E-GEOD-19665

Project description:Transcription profiling by array of human hepatitis B virus (HBV) and hepatitis C virus (HCV) induced hepatocellular (HCC) carcinoma and surrounding noncancerous liver tissue.

2025-01-24 | E-GEOD-19665 | ExpressionAtlas

E-GEOD-12886

Project description:Transcription profiling of by array of human hepatocellular carcinoma cells with RNAi knockdown of Wilm's Tumor 1 gene expression

2025-01-24 | E-GEOD-12886 | ExpressionAtlas

Human normal and peritumor liver tissues LC-MSMS

Project description:The tumor microenvironment (TME) plays an important role in tumorigenesis1. The TME is usually studied in tumor tissue and in relation to tumor progression2,3, which can limit understanding of how the TME is involved in processes associated with initial tumorigenesis as well as tumor recurrence and metastasis after surgery. To describe the underlying mechanisms of human hepatocellular carcinoma (HCC) occurrence and progression, we propose a new concept, the peritumor microenvironment (PME). We collected normal (all biochemical indicators of liver function, imaging examination and histopathology examination were normal) and peritumor (The liver tissues adjacent to the tumor were approximately 2 cm away from the tumor and were taken from patients with HCC who did not receive tumor radiotherapy, tumor chemotherapy or targeted drug therapy before surgery) to perform a proteomic characterization of the PME in peritumor liver tissues.

2022-02-22 | PXD023118 | Pride

Proteome Landscape of Early Stage Hepatocellular Carcinoma Identifies Proteomic Subtypes and New Therapeutic Targets

Project description:Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancers, the second leading cause of cancer mortality worldwide. Although HCC surgical treatment may be curative in the early stages, its five-year overall survival is only 50-70%. Advances in proteomic technologies have expanded the breadth and depth of cancer proteome characterization. Here, we present the largest characterization effort on proteomic profiling of 222 tumor and paired non-tumor tissues in clinically early HCC (Barcelona Clinic Liver Cancer (BCLC) stage 0 and A). Quantitative proteomic data identified three more-refined subtypes in the early- stage cohort of HCC (termed S-I, S-II and S-III) with different clinical outcomes. S-I retained hepatic detoxification and metabolic functions with the best prognosis, S-II increased molecular expression related to proliferation, and S-III showed distinct enrichment of tumor metastasis and immune response pathways and the poorest prognosis. The subtype specific signatures targeted by known FDA approved drugs or inhibitors under clinical investigations for HCC provide a novel resource for HCC therapeutic targets. A new mechanism of disrupted cholesterol homeostasis with aberrant accumulation of cholesteryl esters was also highlighted in S-III. Thus, this study represents the first proteomic stratification of early-stage HCC, providing insights into tumor biology and personalized targeted therapy.

2019-05-29 | PXD006512 | Pride

Proteome Landscape of Early Stage Hepatocellular Carcinoma Identifies Proteomic Subtypes and New Therapeutic Targets - Phosphorylation data

2019-03-01 | PXD008373 | Pride